GlassScriptPhysician profile
Chase Austin Patterson
NPI 1114381571
$1,926.14
in general payments reported to CMS, 2019-2025
25 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $414 · 2023: $739 · 2024: $354 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.21 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $190.59 | 2021-2025 | |
| Astellas Pharma US INC | $140.16 | 2023-2025 | Veozah |
| Channel Medsystems, INC. | $121.27 | 2023 | |
| Exeltis, USA INC. | $116.07 | 2023-2025 | Slynd |
| Organon LLC | $116.01 | 2022-2024 | Nexplanon |
| Intuitive Surgical, INC. | $107.61 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $83.26 | 2023-2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $65.58 | 2022-2024 | Gardasil 9, Gardasil |
| Shield Therapeutics INC | $58.66 | 2023-2024 | Accrufer |
| Medtronic, INC. | $57.11 | 2023-2025 | Truclear |
| Hologic Sales and Service, LLC | $54.11 | 2023-2024 | Acessa Provu System, Aptima |
| Pfizer INC. | $52.45 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.06 | 2022-2023 | |
| Exact Sciences Corporation | $42.27 | 2024-2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Monaghan Medical Corporation | $39.54 | 2023 | Aerobika |
| Sage Therapeutics, LLC | $30.03 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $29.71 | 2023 | Contrave |
| Daiichi Sankyo INC. | $29.67 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.39 | 2022 | |
| Alydia Health | $20.50 | 2021 | |
| Ascend Therapeutics US, LLC | $18.12 | 2021 | |
| Avion Pharmaceuticals | $18.03 | 2023 | Balcoltra |
| Avanos Medical | $16.18 | 2021 | |
| Therapeuticsmd, INC. | $15.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.